AXL and non-small cell lung carcinoma: Particularly, inhibiting AXL in dendritic cells can induce the secretion of type I interferon, promote the expansion of CD8 + T cells, and sensitize NSCLC carrying serine/threonine kinase 11 (STK11/LKB1) mutant to pabolizumab [94].